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Abstract
Hepatoid adenocarcinoma (HAC) is a rare neoplasm with aberrant hepatocellular differentiation. HAC occurs in
extrahepatic organs such as the gastrointestinal tract, testes, ovaries, and lungs and frequently produces alpha-
fetoprotein. A 69-year-old patient was diagnosed clinically with T2aN0M0, stage IB, non-small cell lung carcinoma.
Because the tumor showed tight adhesion to the chest wall, we performed left upper lobectomy, combined
resection of the 3rd and 4th ribs, and lymph node dissection. Pathological examination confirmed the diagnosis of
HAC of the lung (pathological T2aN0M0, stage IB), and four courses of cisplatin and gemcitabine were administered
as adjuvant chemotherapy. Genetic analysis of the epidermal growth factor receptor showed wild type.
Preoperative serum alpha-fetoprotein level, a useful marker of disease progression, was elevated to 4497 ng/ml,
decreasing within the normal range by about 3 months postoperatively. The patient remains alive without
recurrence as of 51 months after surgery.
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Background
Hepatoid adenocarcinoma (HAC) is a rare neoplasm
showing aberrant hepatocellular differentiation. HAC
occurs in extrahepatic organs such as the gastrointes-
tinal tract, testes, ovaries, and lungs and frequently pro-
duces AFP. HAC in any extrahepatic organs is
reportedly associated with poor prognosis. We describe
herein a case of pulmonary HAC treated by complete re-
section and adjuvant chemotherapy.
Case presentation
In March 2011, chest X-ray detected abnormal
shadows in the left lung of a 69-year-old man with a
40-pack-year history of smoking. In 2006, he under-
went surgical resection of early tongue cancer, which
was identified as squamous cell carcinoma. Chest
computed tomography (CT) revealed a mass lesion in
the left segments 1+2, with a diameter of 4.3 cm
(Fig. 1a). The tumor was subpleural and in close con-
tact with the parietal pleura, and a right lower
paratracheal lymph node (#4R) was found to be swol-
len (diameter, 1.0 cm). Fluorodeoxyglucose-positron
emission tomography (FDG-PET) showed abnormal
uptakes in the left lung tumor (maximum standard
uptake value = 5.7), bilateral hilar lymph nodes, and
left supraclavicular lymph nodes (Fig. 1b). CT-guided
needle biopsy confirmed poorly differentiated squa-
mous cell carcinoma in the left lung tumor. The #4R
lymph node showed no malignant findings on endo-
bronchial ultrasonography-transbronchial needle aspir-
ation biopsy (EBUS-TBNA), so we diagnosed clinical
T2aN0M0, stage IB, non-small cell lung carcinoma.
Surgery performed in June 2011 revealed tumor ad-
hering tightly to the chest wall, so we performed left
upper lobectomy, combined resection of the 3rd and
4th ribs, and lymph node dissection.
The resected specimens showed hepatocellular fea-
tures such as a pseudo-biliary tract pattern (Fig. 1c).
Immunohistochemical staining showed tumor cells
with focal positivity for AFP (Fig. 1d), carcinoembryo-
nic antigen (Fig. 1e), glypican 3 (Fig. 1f ), hepatocyte-
specific antigen (Fig. 1g), protein induced by vitamin
K absence or antagonist (Fig. 1h), and CD56. In con-
trast, stains for cytokeratin (CK)7, CK20, thyroid
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transcription factor 1, surfactant apoprotein, CK5/6,
p63, involucrin, chromogranin A, and synaptophysin
all yielded negative results. The tumor showed no
vessel invasion, lymphatic involvement, or lymph node
metastasis. Although the tumor conglutinated to the
chest wall, no invasion of the thoracic wall was evi-
dent on histopathological examination. Pathological
examination confirmed a diagnosis of HAC of the
lung (pathological T2aN0M0, stage IB, according to
the 7th edition TNM classification). Examination for
mutations in the gene for epidermal growth factor
receptor (EGFR) was conducted using polymerase
chain reaction assay, showing wild-type EGFR. Given
the diagnosis of HAC, we examined preoperative
serum AFP levels in stored blood samples. AFP was
found to be elevated to 4497 ng/ml at 1 month
preoperatively, decreasing within the normal range
postoperatively. The patient received four courses of
cisplatin and gemcitabine as adjuvant chemotherapy
and remains alive without recurrence as of 51 months
after surgery.
Discussion
Some cases of AFP-producing lung carcinoma were
reported in the 1980s. Ishikura et al. first reviewed
seven cases of AFP-producing lung carcinoma in 1990
and diagnosed five of the seven cases with HAC [1].
Since that time, 18 cases of HAC of the lung have
been reported [1–10], clarifying the clinicopathologi-
cal and immunohistochemical features. According to
those reports, HAC is associated with large tumor,






Fig. 1 a Chest CT. A mass shadow is present in the left upper lung field (arrow). b Fluorodeoxyglucose-positron emission tomography
shows abnormal uptake in the left lung tumor, bilateral hilar lymph nodes, and left supraclavicular lymph nodes. c Neoplastic cells show
hepatocellular-like differentiation and a partial pseudo-biliary tract pattern (hematoxylin and eosin staining). d Immunohistochemical
staining for alpha-fetoprotein shows focal positivity. e Immunohistochemical staining for carcinoembryonic antigen shows focal positivity.
f Immunohistochemical staining for glypican 3 shows focal positivity. g Immunohistochemical staining for hepatocyte-specific antigen
shows focal positivity. h Immunohistochemical staining for protein induced by vitamin K shows focal positivity
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older patients, regional lymphadenopathies, and dis-
tant metastases [2, 6]. Some studies have described
long-term survival of 2–7 years [6–9]. These cases
were all in the early pathological stage, with two cases
in stage IIB, one in stage IIA, and one in stage IB.
Our case was likewise in stage IB and has so far sur-
vived 51 months postoperatively. From the above
findings, curative resection at an early stage could
contribute to long-term survival.
HAC is an extremely aggressive tumor with poor
prognosis, and effective chemotherapies have yet to
be established. On the other hand, survival for 9 years
and for 37 months has been reported in patients with
clinical stage IV HAC in the lung [10]. Those patients
received multimodal therapy comprising surgery/
tumor debulking and chemoradiotherapy, but no de-
scription of the specific regimen was provided. The
results, however, suggest that intensive treatment can
improve patient survival. We were conducting a clin-
ical trial of cisplatin (CDDP) and gemcitabine (GEM)
as adjuvant chemotherapy for patients with com-
pletely resected pathological stage IB-IIIA non-small
cell lung carcinoma (UMIN000005256) at the time we
encountered the present patient and enrolled him in
the trial. A previous study suggested a survival advan-
tage of adjuvant chemotherapy for stage IB patients
who had tumors ≥4 cm in diameter [11], which was
why we designed this study cohort to include stage IB
tumors.
The possibility of pulmonary metastasis from hepato-
cellular carcinoma was excluded for the lung tumor in
this case, because no liver tumors were apparent on pre-
operative contrast-enhanced CT, FDG-PET, or postoper-
ative ultrasonography. Metastasis from hepatocellular
carcinoma of the stomach or other organs was also ruled
out. HAC of the lung was therefore diagnosed.
In this case, serum AFP levels decreased from
4497 ng/ml at 44 days preoperatively to 125.5 ng/ml at
25 days after surgery and within normal range by 82 days
after surgery. From that time, serum AFP level has
remained within normal limits and no recurrence has
been identified. Serum AFP level could offer a useful
marker of disease progression for HAC.
In our case, EBUS-TBNA was useful for accurate sta-
ging. As the absence of lymph node metastases was con-
firmed by EBUS-TBNA, the patient was able to undergo
surgery while the tumor was still in the early stage.
Conclusions
In conclusion, we encountered a case of HAC in the
lung, representing a rare neoplasm with aberrant
hepatocellular differentiation. The patient underwent
complete resection and adjuvant chemotherapy with
CDDP+GEM and as of the time of writing has
survived without recurrence for 51 months postopera-
tively. Although more cases are required, our findings
suggest that complete resection and multimodal ther-
apy can improve the prognosis for patients with HAC
in the lungs.
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